Novo Nordisk A/S (NVO) — Analyst outlook / Analyst consensus target is. Based on 39 analyst ratings, the consensus is bullish — 1 Strong Buy, 22 Buy, 13 Hold, 3 Sell.
The consensus price target is $47.00 (low: $42.00, high: $54.00), representing an upside of 19.5% from the current price $39.32.
Analysts estimate Earnings Per Share (EPS) of $3.51 and revenue of $44.45B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $22.67 vs est $3.51 (beat +546.2%). 2025: actual $23.06 vs est $3.66 (beat +530.7%). Analyst accuracy: 16%.
NVO Stock — 12-Month Price Forecast
$47.00
▲ +19.53% Upside
Average Price Target
Based on 39 Wall Street analysts offering 12-month price targets for Novo Nordisk A/S, the average price target is $47.00, with a high forecast of $54.00, and a low forecast of $42.00.
The average price target represents a +19.53% change from the last price of $39.32.
Highest Price Target
$54.00
Average Price Target
$47.00
Lowest Price Target
$42.00
NVO Analyst Ratings
Buy
Based on 39 analysts giving stock ratings to Novo Nordisk A/S in the past 3 months
EPS Estimates — NVO
16%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $22.67
vs Est $3.51
▲ 84.5% off
2025
Actual $23.06
vs Est $3.66
▲ 84.1% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — NVO
16%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $290.403B
vs Est $44.446B
▲ 84.7% off
2025
Actual $297.195B
vs Est $47.841B
▲ 83.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
